Recursion names Vicki Goodman as new Chief Medical Officer to advance clinical pipeline.

Recursion Pharmaceuticals announced that Vicki Goodman, M.D., will become the company's new Chief Medical Officer starting April 6, 2026, succeeding David Mauro, M.D., Ph.D. Dr. Goodman brings over 20 years of oncology drug development experience from roles at biotech firms and major pharmaceutical companies, including leadership positions at Merck and Bristol Myers Squibb. Her expertise is expected to help Recursion progress its clinical programs and regulatory milestones, supporting the company's mission to develop innovative medicines using AI-driven technology. David Mauro will transition out after three years, with the company expressing gratitude for his contributions.